An interesting corollary of the above findings is that genes whose expression is upregulated only by the oncogenic MEK1(K57N) mutant (i.e., the sigmoidal-B group) can serve as cancer signature genes, which might serve as cancer diagnostic markers or therapeutic targets. The gene discussed is MAP2K1; the disease is cancer.